Open-label, randomized multicentre phase II study to assess the efficacy and tolerability of sunitinib by dose administration regimen (dose modification or dose interruptions) in patients with advanced or metastatic renal cell carcinoma: study protocol of the SURF trial

Peer Review reports

Original Submission
17 Jan 2018	Submitted	Original manuscript
6 Feb 2018	Reviewed	Reviewer Report - Brian Rini
21 Mar 2018	Author responded	Author comments - Guillaume Mouillet
Resubmission - Version 2
21 Mar 2018	Submitted	Manuscript version 2
23 Mar 2018	Reviewed	Reviewer Report - Steven MacLennan
Resubmission - Version 3
	Submitted	Manuscript version 3
Publishing
27 Mar 2018	Editorially accepted
12 Apr 2018	Article published	10.1186/s13063-018-2613-8

Back to article page